UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/618,687	07/15/2003	Tetsuro Ogawa	P23556	5517
7055 7590 01/12/2007 GREENBLUM & BERNSTEIN, P.L.C. 1950 ROLAND CLARKE PLACE RESTON, VA 20191			EXAMINER	
			GROUP, KARL E	
RESION, VA	20191		ART UNIT	PAPER NUMBER
			1755	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	NOTIFICATION DATE	DELIVERY MODE	
3 MONTHS		01/12/2007	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Notice of this Office communication was sent electronically on the above-indicated "Notification Date" and has a shortened statutory period for reply of 3 MONTHS from 01/12/2007.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

gbpatent@gbpatent.com pto@gbpatent.com

U.S. Patent and Trademark Office PTOL-326 (Rev. 08-06)

Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO/SB/08)

Paper No(s)/Mail Date 12-5-06.

Paper No(s)/Mail Date. _

6) Other: __

Notice of Informal Patent Application

Art Unit: 1755

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 12-5-06 has been entered.

Claim Rejections - 35 USC § 102

- 1. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 2. Claims 12,18,25 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Pfeil et al (4,135,935), for reasons of record.

Applicants' argument that the claims have been amended to clearly recite what components the glass is made from is not persuasive in overcoming the rejection. The starting materials are not considered to patentably distinguish the claimed glass. A glass is an amorphous material, which would no longer include the compound $Ca_3(PO_4)_2$ but a glass that includes CaO and P_2O_5 . Once the glass is formed the composition is no longer a mixture of CaO and $Ca_3(PO_4)_2$. More than one source of CaO may be used to add CaO to the glass, but once the glass is formed the amount of CaO is the total of all the CaO raw materials. It is further argued that Pfeil fails to teach the claimed advantages of "excellent in cell attachment....". Firstly "excellent" is a

Application/Control Number: 10/618,687

Art Unit: 1755

relative term and fails to define any quantitative values, which meet the limitations of the claims. Secondly, Pfeil teaches the composites may be used in the body, replacing teeth, knee joints, jaw bones. Clearly a material used in these applications would have some bio-affinity.

- 3. The rejection of claims 14 and 15 over Pfeil et al is withdrawn in view of applicants' amendment now requiring B_2O_3 in a positive amount.
- 4. Claims 7,9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fujiu et al (4,708,652), for reasons of record.

Applicants' argue Fujiu et al fail to teach the glass as a sintering aid. This is not persuasive because Fujiu et al teach a reaction sintered body therefor the glass would inherently act as a sintering aid. Also Fujiu et al teach the composites have bio-affinity.

The subject matter as a whole would have been obvious to one of ordinary skill in the art at the time the invention was made to have selected the overlapping portion of the range disclosed by the reference because overlapping ranges have been held to be a prima facie case of obviousness, see In re Malagari, 182 U.S.P.Q. 549.

It is also argued that the sintering aid makes it possible to deposit beta wollastonite. It is agreed it is possible to form beta wollastonite however the claims fail to require the presence of wollastonite. Contrary to applicants remarks claim 7 does not require CaF₂ in view of the "at least one" terminology of the claim.

Double Patenting

5. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated

Page 3

Art Unit: 1755

by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

6. Claims 1,3,5,7,9,12-15,17-19,22,24-28 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1,2,4-8,11 of copending Application No. 10/962557. Although the conflicting claims are not identical, they are not patentably distinct from each other because of reasons set forth.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Applicants have not argued this rejection.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karl E. Group whose telephone number is 571-272-1368. The examiner can normally be reached on M-F (6:30-4:00) First Friday Off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jerry Lorengo can be reached on 571-272-1233. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1755

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Primary Examiner Art Unit 1755

Keg 12-29-06